IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today announced that it has received notification from The Nasdaq Stock Market, Inc. that the Nasdaq Listing Qualification Panel has determined to delist...
IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today provided additional information concerning its progress in filing its annual report on Form 10-K for the year ended December 31, 2004 and...
IMPAX Laboratories, Inc. (Nasdaq:IPXLE) today announced that it has entered into a definitive agreement to sell $75 million aggregate principal amount of 3.50% senior subordinated...
IMPAX Laboratories, Inc. (Nasdaq:IPXLE) announced today that it received commitments from Wachovia Bank, National Association and Wachovia Capital Markets, LLC to increase the Company's...
IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today reported steps taken to complete its financial closing and file its Annual Report on Form 10-K for the year ended December 31, 2004. The Company, in...
First graph, first sentence of release should read: xxx a generic version of Rimadyl(R) (Carpofen) 25, 75 and 100 mg Caplets (sted xxx a generic version of Rimadyl(R) (Carpofen) 25, 50 and 75...
IMPAX Laboratories, Inc. (NASDAQ:IPXLE) today announced that the U.S. Food and Drug Administration (FDA) has granted final approval to the Company's Abbreviated New Animal Drug Application (ANADA...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約